Evidence map›Paper›PMID 35297032›Full record

ArticleHistology and histopathology2022

Class II lupus nephritis with podocyte injury in imiquimod-induced lupus-prone mice.

Atsuko Murai, Masaki Yamazaki, Kaori Nishihara, Aki Kito, Sohei Oyama, Naoshi Horiba, Atsuhiko Kato

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Histopathology of spontaneous lesions in FVB/N mice.Journal of toxicologic pathology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Atsuko MuraiTranslational Research Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan. murai.atsuko79@chugai-pharm.co.jp.
Masaki YamazakiTranslational Research Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan.
Kaori NishiharaTranslational Research Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan.
Aki KitoResearch Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan.
Sohei OyamaResearch Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan.
Naoshi HoribaResearch Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan.
Atsuhiko KatoTranslational Research Division, Chugai Pharmaceutical Co., Komakado, Gotemba, Shizuoka, Japan.
Chugai Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus nephritis (LN) is a renal disease presented in systemic lupus erythematosus (SLE) and is divided into 6 classes based on histopathological criteria set by the International Society of Nephrology/Renal Pathology Society. Major mouse models of SLE usually develop class III/IV LN, which are characterized by subendothelial deposits and endocapillary hypercellularity. We examined the pathological features of kidneys in a mouse model of SLE induced by a toll-like receptor 7 agonist, imiquimod (IMQ). In experiment 1, eleven-female FVB/NJcl wild type mice were treated with IMQ on their ear skin 3 times per week. Plasma anti-dsDNA increased from 2 weeks after first IMQ treatment and 2 mice exhibited nephrotic syndrome from 6 weeks. Histopathology revealed eosinophilic mesangial deposits in all mice from 4 weeks. Subsequently, podocytes showed enlargement with vacuolation and their numbers decreased in 6 mice. There was no infiltration of inflammatory cells, subendothelial deposits in glomeruli, or subepithelial deposits in glomeruli. In experiment 2 using 10 mice at 8 weeks after IMQ treatment, the mesangial deposits were observed in all mice and confirmed to be IgG, IgA, IgM, C1q and C3 by immunofluorescence, which corresponds to class II LN. Foot process effacement was detected by transmission electron microscopy and was considered to lead to proteinuria. These mice exhibited pathological characteristics corresponding to class II LN and podocyte injury, which make it distinct from other mouse models of SLE.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisPodocytesAnimalsComplement C1qFemaleImiquimodImmunoglobulin AImmunoglobulin GImmunoglobulin MMiceToll-Like Receptor 7Complement C1qImiquimodImmunoglobulin AImmunoglobulin GImmunoglobulin MToll-Like Receptor 7

Identifiers

PMID35297032
OpenAlexW4221011453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.